)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Enzymatica
Enzymatica (ENZY) investor relations material
Enzymatica Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary16 Jul, 2026
Executive summary
Net sales for Q2 2026 were SEK 7.1 million, down 13.7% year-over-year, mainly due to a large prior-year partner order; H1 2026 net sales were SEK 18.6 million, a 9.6% decrease year-over-year.
Operating loss improved to SEK -12.6 million in Q2 and SEK -26.2 million in H1, reflecting lower operating expenses.
Gross margin declined to 45% in Q2 and 52% in H1, impacted by lower production rates and higher cost of goods sold.
Cash flow from operating activities improved to SEK -11.7 million in Q2 and SEK -18.4 million in H1, driven by reduced expenses and working capital needs.
Strategic focus on international expansion, especially in Germany, Austria, Finland, and Iceland, with new partnerships and organizational strengthening.
Financial highlights
Q2 net sales: SEK 7.1 million (Q2 2025: SEK 8.3 million); H1 net sales: SEK 18.6 million (H1 2025: SEK 20.6 million).
Q2 operating loss: SEK -12.6 million (Q2 2025: SEK -14.9 million); H1 operating loss: SEK -26.2 million (H1 2025: SEK -32.9 million).
Q2 EPS: SEK -0.05 (Q2 2025: SEK -0.06); H1 EPS: SEK -0.11 (H1 2025: SEK -0.13).
Gross margin: 45% in Q2 (53% prior year); 52% in H1 (63% prior year).
Cash and cash equivalents at period end: SEK 13.1 million (H1 2025: SEK 45.3 million).
Outlook and guidance
Continued focus on expanding international partnerships, especially in priority markets.
Nordic strategy refined, with growth opportunities identified in Finland and Iceland.
Updated financial targets expected in late 2026; previous EBIT target under review.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Enzymatica
- Sales fell 6.8% but cost discipline improved; STADA partnership to boost future growth.ENZY
Q1 2026 - Net sales rose 18.3% and ColdZyme gained market share, while losses narrowed and expansion accelerated.ENZYQ4 2025
- Net sales up 25.2% and ColdZyme gains market share, but losses persist amid higher costs.ENZYQ3 2025
- Net sales surged 29% year-over-year, driven by ColdZyme's strong growth and new partnerships.ENZYQ2 2025
- Sales fell but gross margin and cash position improved; rights issue boosts expansion plans.ENZYQ3 2024
- Sales declined and losses widened, but new funding and clinical data may drive future growth.ENZYQ2 2024
- ColdZyme cut rhinovirus viral load by 94% and reduced cold symptoms and sick days in new studies.ENZYStudy Result
- Sales up 30% and ColdZyme's efficacy confirmed, supporting global expansion plans.ENZYQ1 2025
- Core market growth and strong cash position set stage for ColdZyme's 2025 expansion.ENZYQ4 2024
Next Enzymatica earnings date
Q3 202629 Oct, 2026
Enzymatica
Next Enzymatica earnings date
Q3 202629 Oct, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. The company offers ColdZyme, an oral spray for the treatment of common cold; and ear spray for the treatment of otitis media that is primarily intended for infants and small children. Its products are based on its patented enzyme technology, which mimics the body's natural system for managing harmful bacteria. The company markets its products to pharmacies, audiologists, cancer centers, leukemia patients, surgeons, and ENT departments; and online.